Cargando…
Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results‐Medicare analysis of 5235 patients
BACKGROUND: Gastroenteropancreatic neuroendocrine tumors (GEP‐NETs) are increasingly common malignancies and tend to have favorable long‐term prognoses. Somatostatin analogues (SSA) are a first‐line treatment for many NETs. Short‐term experiments suggest an association between SSAs and hyperglycemia...
Autores principales: | Ni, Katherine, Yang, Jeong Yun, Baeg, Kiwoon, Leiter, Amanda C., Mhango, Grace, Gallagher, Emily J., Wisnivesky, Juan P., Kim, Michelle K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551991/ https://www.ncbi.nlm.nih.gov/pubmed/33835729 http://dx.doi.org/10.1002/cnr2.1387 |
Ejemplares similares
-
Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients
por: Baeg, Kiwoon, et al.
Publicado: (2021) -
SUN-626 Survival of Patients with Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus in a Seer-Medicare Cohort
por: Thapi, Sahityasri, et al.
Publicado: (2020) -
Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
por: Appetecchia, Marialuisa, et al.
Publicado: (2010) -
Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
por: Ström, Torbjörn, et al.
Publicado: (2019) -
Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives
por: Baldelli, Roberto, et al.
Publicado: (2014)